| Name | Title | Contact Details |
|---|
Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.
Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.
STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.
Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.